Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

These relatively small companies are developing new cancer therapies that could generate billions in annual sales.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S.Food and Drug Administration (FDA) ...

Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Merck & Co has announced FDA approval for Keytruda (pembrolizumab) combined with chemotherapy for first-line treatment of ...